Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 319.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 291,388 shares of the specialty pharmaceutical company's stock after acquiring an additional 221,903 shares during the quarter. Janus Henderson Group PLC owned 0.90% of Collegium Pharmaceutical worth $8,341,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in COLL. Nisa Investment Advisors LLC grew its holdings in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after purchasing an additional 316 shares during the last quarter. AlphaQuest LLC grew its stake in Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company's stock worth $366,000 after acquiring an additional 374 shares in the last quarter. Foundry Partners LLC increased its position in shares of Collegium Pharmaceutical by 2.4% during the fourth quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company's stock worth $463,000 after acquiring an additional 381 shares during the period. Gallacher Capital Management LLC raised its stake in shares of Collegium Pharmaceutical by 3.3% during the fourth quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company's stock valued at $417,000 after acquiring an additional 470 shares in the last quarter. Finally, Caprock Group LLC grew its stake in Collegium Pharmaceutical by 6.7% in the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company's stock worth $249,000 after purchasing an additional 543 shares in the last quarter.

Collegium Pharmaceutical Price Performance

NASDAQ COLL traded up $0.13 during mid-day trading on Tuesday, hitting $29.96. The stock had a trading volume of 424,409 shares, compared to its average volume of 428,928. The firm's 50 day moving average is $28.15 and its 200 day moving average is $29.80. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a market capitalization of $962.67 million, a price-to-earnings ratio of 12.91 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The business had revenue of $177.76 million for the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Collegium Pharmaceutical's quarterly revenue was up 22.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.45 EPS. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the topic of a number of recent research reports. Needham & Company LLC reissued a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. StockNews.com lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. The trade was a 5.95% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 81,693 shares of company stock worth $2,334,994. Insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.